Kennedy seeks FDA reconsideration of 12 unproven peptides amid safety concerns

The FDA announced July 2026 and February 2027 advisory meetings to consider restoring access to 12 unproven peptides previously removed from a compounding-drug list due to safety risks, despite no new supporting safety or efficacy data. RFK Jr. has championed these peptides, claiming the meetings will “restore science,” while critics warn the Pharmacy Compounding Advisory Committee is under-staffed and at risk of being populated by allies, potentially circumventing standard drug-approval scrutiny. The seven peptides to be reviewed in July are BPC-157, KPV, TB-500, MOTs-C, Emideltide (DSIP), Semax, and Epitalon; the five scheduled for February 2027 are Cathelicidin LL-37, GHK-Cu, Dihexa-acetate, Melanotan II, and Mechano Growth Factor PEG-MGF, all of which lack proven uses.